BeiGene (BGNE)
(Delayed Data from NSDQ)
$156.36 USD
-1.24 (-0.79%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $156.60 +0.24 (0.15%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
BGNE 156.36 -1.24(-0.79%)
Will BGNE be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for BGNE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BGNE
BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why
BeiGene (BGNE) to Report Q4 Earnings: What's in the Cards?
BGNE: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Top Biotech Stocks Worth Adding to Your Portfolio in 2024
Top 5 Momentum Picks for January After a Fabulous 2023
New Strong Buy Stocks for December 22nd
Other News for BGNE
BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE), Immunocore Holdings (IMCR) and COMPASS Pathways (CMPS)
7 Large-Cap Stocks That Can Jump 50% By 2025
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study
BriaCell signs supply agreement with BeiGene for metastatic breast cancer treatment